BOSTON ( TheStreet) -- Earlier today, I posted 13 biotech stock predictions for 2013 . Now, it's your turn to make best guesses on the winner and losers during the coming year.
I threw out a request on Twitter yesterday for 2013 biotech stock predictions. The response was amazing and overwhelming. Thanks to everyone who contributed. I'll be sure to check back throughout the year to check the accuracy of TheStreet's biotech readers.
If you agree, disagree or feel like something is missing from this list, please share your thoughts and comments below.
TheStreet readers' 2013 biotech stock predictions:
AMRN - still independent, launch sales - they will spend much more on mkting, admin, sales than actual gains from product sales. No NCE/— Sport234a2b (@Sport234a) January 1, 2013
my wildest 2013 prediction : $TRGT will be bought in the low 10s— max (@LTbioinvestor) January 1, 2013
@adamfeuerstein $IMUC ict-107 offers statistically significant OS— Shitmylabmatesays (@Shtmylabmatesez) January 1, 2013
@adamfeuerstein my wildest prediction: $CYTK breaks thru $1. benefit in ALS+partner.meets 1ary endpnt in HF— Juan P. Serrate, DVM (@JPZaragoza1) January 1, 2013
@adamfeuerstein Amrn BO price $23 by April— mimosttr (@trstmomi) January 2, 2013
SRPT - expect FDAyes 4 a NDA filing based on current data, a very tough panel review potential late 13, very volatile stk in 13.— Sport234a2b (@Sport234a) January 1, 2013
Prosensa/GSK - sadly, my leaning is a miss for their DMD P3, my problem is w/enrollment criteria, and countries involved.— Sport234a2b (@Sport234a) January 1, 2013
@adamfeuerstein $GSK will buy the rest of $FOLD 5-6 range. $INCY will be bid for by several BP's making it the star of the year.— JNV (@JNVcapital) January 1, 2013
@adamfeuerstein Biotech cos add buy-back provisions in outlicens deals. One co will raise money to exercise; partner will buy the co instead— David Sable (@dbsable) January 1, 2013
@adamfeuerstein $SGMO and other HIV-elimination (cure) technologies emerge as a threat to $GILD $JNJ $MRK $GSK and others— Martin Shkreli (@MartinShkreli) January 1, 2013
@adamfeuerstein inflammation platforms become the biotech theme for 2013— Norcaljosh (@norcaljosh) January 1, 2013
.@adamfeuerstein Mdvn pre-chemo data trumps zytiga by 2 months. Combo trials gives PCA patients an extra 8 months (2014 data?). Dndn dies.— daviesbj (@daviesbj) January 1, 2013
@adamfeuerstein APPA is the best performer out of all of the he "A" stocks(AMRN, ARNA, ALXA have TERRIBLE launches and stock prices suffer)— Chet Stedman (@ChetStedman5) January 1, 2013
@adamfeuerstein Mnkd will be the biotech of the year.— Al Marino (@optiontrader78) January 1, 2013
@adamfeuerstein My prediciton?No matter what biotech I am in, I'm gonna get f----d one way or the other.— TraderNeal (@traderneal) January 1, 2013
@adamfeuerstein I predict the anti-PD1s will be big successes in multiple solid tumor types. Lung and melanoma in particular. $BMY and $MRK— Chris Ahlstrand (@ahlstrac) January 1, 2013